Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)

v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Previously Reported
Retroactive application of recapitalization
Common Stock
Common Stock
Previously Reported
Common Stock
Retroactive application of recapitalization
Additional Paid-in Capital
Additional Paid-in Capital
Previously Reported
Additional Paid-in Capital
Retroactive application of recapitalization
Accumulated Deficit
Accumulated Deficit
Previously Reported
Beginning balance (in shares) at Dec. 31, 2019 0 153,758,348 (153,758,348)                
Beginning balance at Dec. 31, 2019 $ 0 $ 129,921 $ (129,921)                
Ending balance (in shares) at Dec. 31, 2020 0 324,370,424                  
Ending balance at Dec. 31, 2020 $ 0 $ 202,056                  
Beginning balance (in shares) at Dec. 31, 2019       63,204,426 65,196,490 (1,992,064)          
Beginning balance at Dec. 31, 2019 2,978 $ (126,943) $ 129,921 $ 6 $ 59 $ (53) $ 170,600 $ 40,626 $ 129,974 $ (167,628) $ (167,628)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income (loss) (39,650)                 (39,650)  
Issuance of common stock upon exercise of stock options (in shares)       5,318,139              
Issuance of common stock upon exercise of stock options 66     $ 1     65        
Issuance of Series P-2 convertible preferred stock (in shares)       27,989,240              
Issuance of Series P-2 convertible preferred stock 63,932     $ 3     63,929        
Conversion of promissory notes to Series P-2 convertible preferred stock (in shares)       3,507,984              
Conversion of promissory notes to Series P-2 convertible preferred stock 8,203           8,203        
Early exercised stock options vested 21           21        
Stock-based compensation 666           666        
Repurchase of unvested restricted common stock (in shares)       (3,230)              
Ending balance (in shares) at Dec. 31, 2020       100,016,559              
Ending balance at Dec. 31, 2020 36,216     $ 10     243,484     (207,278)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income (loss) (125,874)                 (125,874)  
Business combination, net of redemptions and equity issuance costs and PIPE financing, net (in shares)       41,249,985              
Business combination, net of redemptions and equity issuance costs and PIPE financing, net 300,745     $ 4     300,741        
Issuance of common stock upon exercise of common stock warrants (in shares)       7,177,885              
Issuance of common stock upon exercise of common stock warrants, net 82,546     $ 1     82,545        
Issuance of common stock upon exercise of stock options (in shares)       2,180,168              
Issuance of common stock upon exercise of stock options 62           62        
Issuance of Series D convertible preferred stock upon exercise of warrants (in shares)       2,020,034              
Issuance of Series D convertible preferred stock upon exercise of warrants 20,877           20,877        
Vesting of RSU (in shares)       61,015              
Early exercised stock options vested 111           111        
Stock-based compensation $ 11,434           11,434        
Repurchase of unvested restricted common stock (in shares)       (433,359)              
Ending balance (in shares) at Jan. 02, 2022 152,272,287     152,272,287              
Ending balance at Jan. 02, 2022 $ 326,117     $ 15     659,254     (333,152)  
Beginning balance (in shares) at Jul. 13, 2021 563,316,738                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of Series P-2 convertible preferred stock (in shares) 12,500,000                    
Ending balance (in shares) at Jul. 14, 2021 145,245,628                    
Beginning balance (in shares) at Jan. 02, 2022 152,272,287     152,272,287              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net income (loss) $ (51,622)                 (51,622)  
Issuance of common stock upon exercise of common stock warrants (in shares)       4,126,466              
Issuance of common stock upon exercise of common stock warrants, net $ 47,452           47,452        
Issuance of common stock upon exercise of stock options (in shares) 381,497     381,497              
Issuance of common stock upon exercise of stock options $ 2,379           2,379        
Issuance of common stock under employee stock purchase plan (in shares)       229,249              
Issuance of common stock under employee stock purchase plan 1,900           1,900        
Vesting of RSU (in shares)       621,179              
RSUs vested, net of shares withheld for taxes (587)           (587)        
Early exercised stock options vested 122           122        
Stock-based compensation $ 30,666           30,666        
Repurchase of unvested restricted common stock (in shares)       (168,876)              
Ending balance (in shares) at Jan. 01, 2023 157,461,802     157,461,802              
Ending balance at Jan. 01, 2023 $ 356,427     $ 15     $ 741,186     $ (384,774)